PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/583,056
Filing Date	June 14, 2006
First Named Inventor	Katherine S. Bowdish
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALEX-P01-112

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-20030232745-A1	12-18-2003	Olson et al.	
	AB	US-7,148,329	12-12-2006	Figdor et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	BA	WO-93/01820-A2		Bristol-Myers Squibb		
	BB	WO-96/23882-A1		Rockefeller University		
	BC	WO-98/41633-A1		Incyte Pharmaceuticals		
	BD	WO-98/02456-A2 & A3		Incyte Pharmaceuticals		
	BE	WO-98/28332-A2 & A3		University of Texas		
	BF	WO-98/49306-A1		Incyte Pharmaceuticals		
	BG	WO-98/55508-A2 & A3		Sagami Chemical		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	Andre et al., "Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage," Journal of Virology, 72(2):1497-1503 (1998).	
	CB	Baribaud et al., "Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN," Journal of Virology, 75(21):10281-10289 (2001).	
	CC	Cohen, Jon, "AIDS Research: Novel Protein Delivers HIV to Target Cells," Science, 287:1567 (2000).	
	CD	Curtis et al., "Sequence and Expression of a Membrane-Associated C-type Lectin that Exhibits CD4-Independent Binding of Human Immunodeficiency Virus Envelope Glycoprotein gp120," Proc. Natl. Acad. Sci. USA, 89:8356-8360 (1992).	
	CE	Engering et al., "The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells," J. of Immun., 168:2118-2126 (2000).	
	CF	Feinberg et al., "Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and SC-SIGNR," Science, 294:2163-2166 (2001) (with Supplementary Material published electronically on the*Science* website, 6 pgs.).	
	CG	Geijtenbeek et al., "Identification of DC-SIGN, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses," Cell, 100:575-585 (2000).	
	CH	Geijtenbeek et al., "DC-SIGN, a Dendritic Cell-Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells," Cell, 100:587-597 (2000).	
	CI	Geijtenbeek et al., "Identification of Different Binding Sites in the Dendritic Cell-Specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1," J. Biol. Chem., 227(13):11314-11320 (2002).	

Examiner Signature		Date Considered	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/583,056
Filing Date	June 14, 2006
First Named Inventor	Katherine S. Bowdish
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	ALEX-P01-112

	~~CJ~~	~~Genbank Accession No. AB015620~~	
	CK	Gruber et al., "Functional Aspects of Binding of Monoclonal Antibody DCN46 to DC-SIGN on Dendritic Cells," Immunology Letters, 84:103-108 (2002).	
	CL	Hong et al., "Human Immunodeficiency Virus Envelope (gp120) Binding to DC-SIGN and Primary Dendritic Cells Is Carbohydrate Dependent but Does Not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding," Journal of Virology, 12855-12865 (2002).	
	CM	"Human CD209: anti-Human CD209 (DC-SIGN) antibody", eBioscience, http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm, 1/5/2004.	
	CN	Jameson et al., "Expression of DC-SIGN by Dendritic Cells of Intestinal and Genital Mucosae in Humans and Rhesus Macaques," Journal of Virology, 76:1866-1875 (2002).	
	CO	Janeway et al., Immunobiology, (5th ed.), Garland Publishing, New York, p.691 (2001).	
	CP	Knight and Patterson, "Bone Marrow-Derived Dendritic Cells, Infection with Human Immunodeficiency Virus, and Immunopathology," Annu. Rev. Immunol., 15:593-615 (1997).	
	CQ	Manca et al., "Dendritic Cells are Potent Antigen-Presenting Cells for an Vitro Induction of Primary Human CD4+ T-Cell Lines Specific for HIV gp120," Journal of Acquired Immune Deficiency Syndromes, 7:15-23 (1994).	
	CR	Mitchell et al., "A Novel Mechanism of Carbohydrate Recognition by the C-type Lectins DC-SIGN and DC-SIGNR," The Journal of Biological Chemistry, 276:28939-28945 (2001).	
	CS	Product information for DCN46, "Purified Mouse Anti-Human Monoclonal Antibody", BD PharMingen Technical Data Sheet, BD Biosciences Product Information sheet, Catalog Number 551186, 05/01/01.	
	CT	Pohlmann et al., "DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus," J. of Virology, 75(10):4664-4672 (2001).	
	CU	Soilleux et al., "Cutting Edge: DC-SIGN; a Related Gene, DC-SIGNR; and CD23 Form a Cluster on 19p13[1,2]", Immunology, 2937-2942 (2000).	
	CV	Steinman, Ralph M., "DC-SIGN: A Guide to Some Mysteries of Dendritic Cells," Cell, 287:491-494 (2000).	
	CW	Toda et al., "HIV-1-Specific Cell-Mediated Immune Responses Induced by DNA Vaccination were Enhanced by Mannan-Coated Liposomes and Inhibited by Anti-Interferon-γ Antibody," Immunology, 92:111-117 (1997).	
	CX	Tsunetsugu-Yokota et al., "Efficient Virus Transmission from Dendritic Cells to CD4+T Cells in Response to Antigen Depends on Close Contact through Adhesion Molecules," Virology, 239:259-268 (1997).	
	CY	Vazeux et al., "Cloning and Characterization of a New Intercellular Adhesion Molecule ICAM-R," Nature, 360:485-488.	
	CZ	Wu et al., "Functional Evaluation of DC-SIGN Monoclonal Antibodies Reveals DC-SIGN Interactions with ICAM-3 Do Not Promote Human Immunodeficiency Virus Type I Transmission," J. Virol., 76(12):5905-5914 (2002).	
	CA1	Zoeteweij and Blauvelt, "HIV-Dendritic Cell Interactions Promote Efficient Viral Infection of T Cells," J. Biomed. Sci., 5:253-259 (1998).	

date?

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Gerald Ewoldt/	Date Considered	09/27/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./